What medications should be prescribed on discharge for a patient with newly diagnosed atrial fibrillation (AF) of unknown duration, prior to seeing a cardiologist?

Discharge Medications for Newly Diagnosed Atrial Fibrillation of Unknown Duration

Immediate Anticoagulation is Mandatory

For newly diagnosed AF with unknown duration, you must initiate anticoagulation immediately before discharge, as unknown duration is treated identically to AF ≥48 hours duration. 1

The 2019 AHA/ACC/HRS guidelines are unequivocal: patients with AF of unknown duration require therapeutic anticoagulation for at least 3 weeks before any elective cardioversion and at least 4 weeks after cardioversion, regardless of whether cardioversion is performed. 1 This applies whether you plan cardioversion or not—the unknown duration mandates assuming prolonged AF with thromboembolic risk.

Anticoagulation Selection Algorithm

Direct oral anticoagulants (DOACs) are strongly preferred over warfarin as first-line therapy. 1

Choose one of the following DOACs 1, 2:

• Apixaban 5 mg twice daily (or 2.5 mg twice daily if ≥2 of: age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL)
• Rivaroxaban 20 mg once daily (15 mg if CrCl 15-50 mL/min)
• Edoxaban 60 mg once daily (30 mg if CrCl 15-50 mL/min or weight ≤60 kg)
• Dabigatran 150 mg twice daily (110 mg twice daily if age ≥80 years or high bleeding risk)

If DOACs are contraindicated (mechanical valve, severe mitral stenosis, CrCl <15 mL/min), use warfarin with target INR 2.0-3.0. 1, 3

Critical Anticoagulation Caveats

• Do NOT withhold anticoagulation to "wait for cardiology"—this is a Class I recommendation that must be initiated immediately. 1
• Avoid apixaban in patients with antiphospholipid syndrome (especially triple-positive antibody testing), as it increases thrombotic risk. 2
• Long-term anticoagulation decisions are based on CHA₂DS₂-VASc score, NOT on whether the patient remains in AF—this is a common and dangerous pitfall. 1, 4

---

Rate Control Medication is Essential

Initiate rate control therapy immediately, targeting resting heart rate <110 bpm (lenient control) as the initial goal. 4, 5

Rate Control Drug Selection Based on Cardiac Function

For patients with preserved ejection fraction (LVEF >40%): 1, 4

• Beta-blockers (metoprolol 25-100 mg twice daily, or atenolol 25-100 mg daily) OR
• Non-dihydropyridine calcium channel blockers (diltiazem 60-120 mg three times daily or 120-360 mg extended-release daily; verapamil 40-120 mg three times daily or 120-480 mg extended-release daily)

For patients with reduced ejection fraction (LVEF ≤40%) or heart failure: 1, 4

• Beta-blockers (carvedilol, metoprolol succinate) AND/OR
• Digoxin 0.0625-0.25 mg daily
• Avoid calcium channel blockers in this population due to negative inotropic effects 4

For patients with COPD or active bronchospasm: 4

• Use diltiazem or verapamil (avoid beta-blockers)
• Beta-1 selective blockers in small doses may be considered cautiously 1

Rate Control Monitoring

If monotherapy fails to achieve adequate rate control, combine digoxin with a beta-blocker or calcium channel blocker for synergistic effect at rest and during exercise. 1, 4 Never use digoxin as monotherapy for paroxysmal AF—this is a Class III (harm) recommendation. 4

---

Discharge Instructions and Follow-up

Patient Education Requirements

Educate the patient on 6, 4:

• Stroke warning signs: sudden weakness, speech difficulty, vision changes, severe headache, loss of balance
• Bleeding warning signs: blood in urine/stool, severe bruising, prolonged bleeding from cuts, coughing up blood
• Medication adherence: Do not miss doses; refill prescriptions before running out
• Dietary considerations (if on warfarin): maintain consistent vitamin K intake

Mandatory Cardiology Referral

Schedule outpatient cardiology follow-up within 1-2 weeks for 1, 4:

• Rhythm control strategy discussion (cardioversion vs. long-term rate control)
• Antiarrhythmic drug consideration if symptomatic despite rate control
• Evaluation for catheter ablation candidacy
• Long-term anticoagulation plan refinement based on CHA₂DS₂-VASc score

Laboratory Monitoring Before Cardiology Visit

• If on warfarin: INR check within 3-5 days, then weekly until stable 4, 3
• If on DOACs: baseline renal function (repeat at least annually) 4
• Thyroid function, electrolytes, complete blood count to identify reversible causes 4

---

What NOT to Prescribe at Discharge

Do not initiate antiarrhythmic drugs (flecainide, propafenone, sotalol, amiodarone, dofetilide) at discharge without cardiology consultation, as these require careful patient selection based on structural heart disease, QT interval monitoring, and hospitalization for initiation in some cases. 1 Dofetilide specifically should never be initiated outpatient—this is a Class III (harm) recommendation. 1

Do not prescribe aspirin or antiplatelet agents as stroke prevention—they are substantially inferior to anticoagulation and should only be used if anticoagulation is absolutely contraindicated. 6, 4